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Motor cortexEvidence from human post mortem, in vivo and animal model studies implicates the neuroimmune system and
activated microglia in the pathology of amyotrophic lateral sclerosis. The study aim was to further evaluate
in vivo neuroinﬂammation in individuals with amyotrophic lateral sclerosis using [11C]-PBR28 positron emission
tomography. Ten patients with amyotrophic lateral sclerosis (seven males, three females, 38–68 years) and ten
age- and [11C]-PBR28 binding afﬁnity-matched healthy volunteers (six males, four females, 33–65 years) com-
pleted a positron emission tomography scan. Standardized uptake values were calculated from 60 to 90 min
post-injection and normalized to whole brain mean. Voxel-wise analysis showed increased binding in the
motor cortices and corticospinal tracts in patients with amyotrophic lateral sclerosis compared to healthy
controls (pFWE b 0.05). Region of interest analysis revealed increased [11C]-PBR28 binding in the precentral
gyrus in patients (normalized standardized uptake value = 1.15) compared to controls (1.03, p b 0.05). In pa-
tients those values were positively correlated with upper motor neuron burden scores (r = 0.69, p b 0.05),
and negatively correlated with the amyotrophic lateral sclerosis functional rating scale (r = –0.66, p b 0.05).
Increased in vivo glial activation in motor cortices, that correlates with phenotype, complements previous histo-
pathological reports. Further studies will determine the role of [11C]-PBR28 as a marker of treatments that target
neuroinﬂammation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder
in which upper and lower motor neurons degenerate leading to pro-
gressive muscle weakness, respiratory failure and death often within
2–5 years (Ferraiuolo et al., 2011). Riluzole, the only FDA-approved
treatment provides a modest survival beneﬁt (Lacomblez et al., 1996),S-R, amyotrophic lateralsclero-
rate; MR,magnetic resonance;
ron emission tomography; SUV,
in;UMNB, uppermotorneuron
search Institute, Massachusetts
on, 02114 MA, USA. Tel.:+617
s Center for Biomedical Imaging,
Suite 2301, Charlestown, 02129
ooker),
. This is an open access article underbut there are no available treatments that prevent or stop disease pro-
gression and current animal models have not yet successfully predicted
treatment response in people (Atassi et al., 2012; Ferraiuolo et al.,
2011). A substantial body of evidence implicates the neuroimmune sys-
tem and speciﬁcally activated microglia in ALS pathophysiology (Appel
et al., 2011). In post mortem studies increased activated microglia are
correlated with increased upper motor neuron symptoms and faster
disease progression (Brettschneider et al., 2012). Despite years of re-
search, the fundamental question of whether the immune response
observed in ALS is primary or secondary, beneﬁcial or harmful, or a
combination of both, has not yet been clearly answered.
Given the disconnection between mouse models and human dis-
ease, it is critical to develop methods to examine disease biology
in vivo in patients with ALS. With positron emission tomography
(PET) a radiotracer is used to visualize and quantify molecular interac-
tions with high sensitivity. Several PET radiotracers have been devel-
oped to image activated microglia and most provide contrast by
binding the 18 kDa translocator protein (TSPO), formerly known as
the peripheral benzodiazepine receptor (PBR), which is highlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Lavisse et al., 2012). The ﬁrst application of TSPO PET imaging in
patients with ALS conﬁrmed widespread microglial activation (Turner
et al., 2004). This pioneering study conducted with the radioligand
[11C]-(R)-PK11195 showed increased binding in the motor cortex,
pons, dorsolateral prefrontal cortex and thalamus in a group of ALS pa-
tients. Older generation TSPO radioligands such as [11C]-(R)-PK11195
suffered from high levels of non-speciﬁc binding and poor signal-to-
background ratio (Kreisl et al., 2010). Increased TSPO expression,
assessed using the radioligand [18F]-DPA-714, was subsequently
reported in the primary motor cortex, supplementary motor area
as well as temporal cortex of patients with ALS, thereby providing
additional support for a role for inﬂammatory processes in ALS
(Corcia et al., 2012).
The radioligand [11C]-PBR28, developed at the National Institute
of Mental Health, was shown to exhibit 80 times more speciﬁc binding
compared to [11C]-(R)-PK11195 in rhesusmacaques (Kreisl et al., 2010).
The aim of this proof-of-concept study was to investigate [11C]-PBR28
binding in a group of individuals with ALS compared to a matched
group including for TSPO polymorphism of healthy controls and to
investigate whether the [11C]-PBR28 radiotracer could better sub-
categorize ALS patients based on the anatomical regions with the
highest disease burden.
2. Materials and methods
The study was conducted at the Athinoula A. Martinos Center for
Biomedical Imaging at Massachusetts General Hospital. The protocol
was approved by the Institutional Review Board and the Radioactive
Drug Research Committee. All participants provided written informed
consent according to the Declaration of Helsinki.
2.1. Participants
Fourteen ALS patients were initially screened for the study.
To meet inclusion criteria, participants had to fulﬁll the revised EL
Escorial criteria (Brooks et al., 2000) for possible, probable, proba-
ble laboratory-supported or deﬁnite ALS, not have any signs of
frontotemporal dementia and could not be taking any anti-
inﬂammatory or immunosuppressant medications or benzodiaze-
pines. None of the patients had a familial history of ALS.
[11C]-PBR28, along with all second-generation TSPO radiotracers
to date, has differential binding afﬁnity to TSPO depending on an
Ala147Thr polymorphism in the TSPO gene with Ala/Ala leading
to high-, Ala/Thr to mixed-, and Thr/Thr to low-afﬁnity binding
(Kreisl et al., 2013; Owen et al., 2012). This binding afﬁnity differ-
ence can be detected by standardized uptake value (SUV) measure-
ments (Yoder et al., 2013), and needs to be controlled for in cross-
sectional study designs. All participants were tested for TSPO
polymorphism and low afﬁnity binders were excluded, resulting in
the exclusion of two individuals with ALS with Thr/Thr Ala147Thr
polymorphism. Two additional individuals with ALS were not able
to lie comfortably on the scanner table and therefore data could not
be acquired.
Of the remaining 10 individuals with ALS who successfully
completed scanning, seven had limb-onset ALS and three had
bulbar-onset ALS. The clinical outcomes obtained from the partici-
pants with ALS included the revised ALS functional rating scale
(ALSFRS-R) (Cedarbaum et al., 1999), upper motor neuron burden
scale (UMNB) (Ellis et al., 1999), and vital capacity (VC). The
ALSFRS-R assesses general functional status and ranges from 48
(normal level of functioning) to 0, with lower scores indicating in-
creased disability. The UMNB measures the following deep tendon
(scores 0–4) and pathological reﬂexes (present — 1 or absent — 0):
biceps, brachioradialis, triceps, knee jerk, ankle jerk, Hoffman,
Babinski, and jaw jerk. The total UMNB score ranges from 0 to 45,with 0 representing no reﬂex involvement, and 45 maximal abnor-
mal UMNB. VC measures respiratory functioning and is expressed
as a percentage out of 100%, with 100 being normal and scores
below 100 indicating decreased lung capacity. The 10 participants
with ALS were compared to 10 healthy controls matched for age
and TSPO binding afﬁnity.
2.2. Radiotracer synthesis and data acquisition
[11C]-PBR28 was produced in-house using a procedure modiﬁed
from the literature (Imaizumi et al., 2007). Brieﬂy, the desmethyl
precursor (1.0 mg in 100 µL) was loaded into a 5 mL stainless steel
loop for reaction with CH3I using the Wilson captive solvent method
(Wilson et al., 2000). [11C]-PBR28 was puriﬁed by reversed-phase
chromatography and reformulated by solid-phase extraction in 10%
ethanol/saline and then aseptically ﬁltered. The radioligand was
injected as slow intravenous bolus, with a median administered
dose of 419.49 mBq for patients with ALS and 419.08 mBq for con-
trols. PET data were acquired over 90 min and stored in list-mode
format.
Participants were scanned on a Siemens magnetic resonance (MR)/
PET scanner consisting of a dedicated brain avalanche photodiode-
based PET scanner operating in the bore of a 3 T whole-body MR
scanner, and an 8-channel head coil was used. This combined MR/PET
scanner allowed the simultaneous acquisition of MR and PET data
(Catana et al., 2010). An anatomical scan, a multi-echo MP-RAGE
(TR = 2530, TE 1–4 = 1.64, 3.5, 5.36, 7.22 ms, ﬂip angle = 7°, voxel
size = 1 mm isotropic) was acquired at the beginning of the scan.
2.3. Data analysis
After acquisition, PET imageswere reconstructed using the Ordinary
Poisson Ordered Subset Expectation Maximization 3D algorithm from
prompt coincidences, with corrections for normalization, dead time,
isotope decay, photon attenuation and expected random and scatter
coincidences. Attenuation correction maps were created using MR-
basedmethods (Izquierdo-Garcia et al., 2014). SUV imageswere created
for radioactivity in the ﬁeld of view 60–90 min post-radioligand injec-
tion. To account for motion that may have occurred between MP-
RAGE acquisition and the 60–90 min post-injection time point corre-
sponding to the PET frame of interest, SUV60–90 min was generated in a
two-step procedure. First, a SUV60–90 min image was created for each
subject using an attenuation correction map computed from the native
MP-RAGE. Subsequently, a new attenuation map was created based on
the registration of the native MP-RAGE with the SUV60–90 min image
obtained in this ﬁrst reconstruction using FreeSurfer3s spmregister. A
ﬁnal SUV60–90 minwas then reconstructed based on this newattenuation
correction image well registered with the 60–90 min PET data. Individ-
ual SUV60–90 min images were then registered to MNI (Montreal Neuro-
logical Institute) space, spatially smoothed (6 mm full width at half
maximum), and intensity-normalized to a mean of 1 (SUVR60–90 min)
in order to account for differences in global signal across subjects, as
previously done for [11C]-PBR28 (Loggia et al., 2015). SUVR60–90 min in
MNI was then fed into a voxelwise between-group analysis. FSL3s ran-
domize was used to perform a permutation-based nonparametric
two-sample unpaired t-test (n permutation = 10,000, 5 mm variance
smoothing) with TSPO genotype added as a nuisance regressor.
Threshold-free cluster enhancement (TFCE) was applied and p values
were family-wise error rate (FWE) corrected (pFWE b 0.05) (Nichols
and Holmes, 2002).
An a priori region of interest for the left and right precentral gyri was
selected for each subject using Freesurfer3s automated parcellation.
Two-tailed Mann–Whitney was used to assess between-group differ-
ences. To investigate whether [11C]PBR-28 binding correlated with ALS
disease severity, Spearman3s r was used to investigate for the presence
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and UMNB scores, ALSFRS-R, and disease duration.
3. Results
3.1. Study participants
Ten ALS patients (7 males, 3 females, 6 high- and 4 mixed-afﬁnity
binders), with a mean age of 53.2 years (SD = 10.8, range 38–68) suc-
cessfully completed scanning and were compared to healthy controls
matched for binding afﬁnity and age (6 males, 4 females, 6 high- and
4 mixed-afﬁnity). Healthy controls were on average 51.1 years old
(SD = 11.0, range 33–65). See Table 1.
3.2. Individual data in patients with ALS and group means
Visual inspection of SUVR60–90 min images revealed regional increase
in the precentral gyrus in patients with ALS with limb-onset, and not in
the patients with ALSwith bulbar-onset disease. See Fig. 1A for individ-
ual data projected onto the MNI template and Fig. 1B for means for the
ALS group, including comparisons between limb- and bulbar-onset pa-
tients, and the control group. Patients with limb-onset weakness
showed increased binding in the precentral gyri and patients with
bulbar-onset weakness showed increased binding in the brainstem
(Fig. 1B, top two rows).
3.3. Whole brain between-group analysis
The unpaired t-test conducted on the whole brain static
SUVR60–90 min image showed that the ALS group has increased
[11C]-PBR28 binding in the bilateral motor cortices, including the pri-
marymotor cortex (M1) and supplementarymotor area, as well as in
the upper region of the corticospinal tract pFWE b 0.05, Fig. 1C. There
were no regions in which controls showed increased binding com-
pared to individuals with ALS.
Given that to date only TSPO genotype has been shown to inﬂuence
[11C]-PBR28 binding, we are reporting the results of a voxelwise
analysis, which added only TSPO genotype (Ala/Ala vs. Ala/Thr) as a
regressor of no interest. However, an additional analysis conducted
using TSPO genotype, as well as age and sex as regressors of no
interest, led to the same brain regions being signiﬁcantly increased inTable 1
Participant characteristics.
Subject TSPO genotype Age Sex Site of onset
ALS-1 Ala/Ala 53 M Left lower limb
ALS-2 Ala/Ala 48 M Left upper limb
ALS-3 Ala/Ala 38 F Left upper limb
ALS-4 Ala/Thr 68 M Right & left lower lim
ALS-5 Ala/Thr 55 M Right upper limb
ALS-6 Ala/Thr 48 M Right lower limb
ALS-7 Ala/Thr 39 M Right upper limb
ALS-8 Ala/Ala 51 M Bulbar
ALS-9 Ala/Ala 66 F Bulbar
ALS-10 Ala/Ala 66 F Bulbar
Mean for ALS 60% Ala/Ala 53.2 ± 10.8 70% M 70% Limb
CTRL-1 Ala/Ala 59 M N/A
CTRL-2 Ala/Ala 51 M N/A
CTRL-3 Ala/Ala 33 M N/A
CTRL-4 Ala/Ala 65 F N/A
CTRL-5 Ala/Ala 58 F N/A
CTRL-6 Ala/Ala 52 F N/A
CTRL-7 Ala/Thr 60 M N/A
CTRL-8 Ala/Thr 43 M N/A
CTRL-9 Ala/Thr 34 M N/A
CTRL-10 Ala/Thr 56 F N/A
Mean for CTRL 60% Ala/Ala 51.1 ± 11.0 60% Mthe ALS vs. control group comparison as the analysis where only TSPO
genotype was added as a regressor.
3.4. Region of interest analysis
Compared to controls, individuals with ALS exhibited signiﬁcantly
increased binding in the bilateral precentral gyri, a priori identiﬁed re-
gion of interest. ALS (median, range): 1.15, 1.05–1.30, controls: 1.03,
0.99–1.18, p b 0.05 (Fig. 2). In ALS patients, SUVR60–90 min of the right
precentral gyrus was positively correlated with UMNB scores, r =
0.69, p b 0.05 (Fig. 3A) and negatively correlated with functional status
measured by ALSFRS-R, r = –0.66, p b 0.05 (Fig. 3B). Disease duration
did not correlate with SUVR60–90 min in the precentral gyrus.
An exploratory comparison of individuals with limb vs. bulbar
onset ALS showed that individuals with limb onset (N = 7) had a
signiﬁcantly higher SUVR60–90 min than individuals with ALS with
bulbar onset (N = 3) in the precentral gyrus (p b 0.05).
4. Discussion
Our study demonstrates increased in vivo [11C]-PBR28 binding in
the motor cortices and corticospinal tract in patients with ALS. This
ﬁnding is consistent with the ﬁrst microglial PET study in ALS patients
(Turner et al., 2004), as well as histopathological studies reporting
increased activated microglia near degenerating motor neurons
(Brettschneider et al., 2012; Henkel et al., 2004; Kawamata et al.,
1992), suggesting that [11C]-PBR28 PET is a robust candidate as
an in vivo biomarker of inﬂammation in ALS. This is the ﬁrst study
conducted in patients with ALS using a second-generation TSPO
radioligand, while controlling for TSPO binding afﬁnity genotype. In
accordance with our ﬁndings, previous studies investigating TSPO
binding reported increases in motor cortices (Corcia et al., 2012;
Turner et al., 2004). Compared to previous tracers, [11C]-PBR28
SUVR images provide higher contrast in regions of activated glia,
which represents a considerable advantage when evaluating neuro-
inﬂammation in individual patients.
Apart from clinical signs, there are no reliable biomarkers of upper
motor neuron dysfunction in ALS. [11C]-PBR28 PET could represent a
marker of upper motor neuron injury that can complement electromy-
ography as an indicator of lower motor neuron injury. Notably, the
individual scores from the UMNB scale and ALSFRS-R were correlated
with [11C]-PBR28 binding, suggesting a clinical relevance of brainDisease duration (months) VC ALSFRS-R UMNB
26 77 32 39
22 100 31 25
9 106 35 35
bs 21 66 41 21
16 93 36 28
11 89 42 34
57 76 30 33
11 76 45 17
34 78 35 28
13 60 37 25
22.0 ± 14.6 82.1 ± 14.6 36.4 ± 4.9 28.5 ± 6.8
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
Fig. 1. [11C]-PBR28 SUVR60–90 min images and statistical maps for between-group differences. A. [11C]-PBR28 SUVR60–90 min for 10 individual ALS patients and 10 age- and binding afﬁnity-
matched healthy controls. SUVR60–90 min data are projected onto the MNI template in radiological orientation and shown at MNI coordinate z=+64. B. Mean [11C]-PBR28 SUVR60–90 min
images for the ALS and control groups, including comparisons between limb- and bulbar-onset patients, shown at MNI coordinates x=−2, y =−20, and z=+64. C. Brain regions that
exhibit signiﬁcantly higher binding in ALS compared to the control group in the voxelwise whole brain analysis, pFWE b 0.05, shown at MNI coordinates x=−8, y =−20, and z =+64.
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tively correlated with microglial PET tracer uptake in the motor cortex
using [11C]-PK11195 (Turner et al., 2004). Additionally, our exploratory
analysis showed that individuals with bulbar-onset did not show the in-
creased binding in themotor cortex to the extent that it was observed in
patients with limb-onset ALS. On the other hand, individuals with
bulbar-onset ALS showed regional increases in PBR28 uptake in thebrainstem. This suggests that [11C]-PBR28 binding has a strong anatom-
ical relevance to ALS clinical phenotype (Fig. 1B). The increase in PBR28
uptake in the brainstem could represent inﬂammation around the
lowermotor neurons of the cranial nerves as all three bulbar-onset sub-
jects had evidence of lower motor neuron dysfunction on examination.
This emphasizes the importance of exploring PBR28 PET imaging in the
spinal cord to better characterize this observation. On the other hand,
Fig. 2. Increased glial activation in primary motor cortex in ALS. Boxplots for [11C]-PBR28
SUVR60–90 min for the precentral gyrus a priori ROI for individuals with ALS and healthy
controls. Patients with ALS exhibit signiﬁcantly increased binding in the motor cortex
compared to healthy controls, *p b 0.05.
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cortex in the bulbar-onset patients is unclear. Considering the very
small sample size of this subgroup (N= 3) we consider these data pre-
liminary and caution against over-interpretation of these ﬁndings.
The main limitation of our study is the relatively small sample size.
However, both the two previously published PET studies in ALS usingFig. 3. Correlation between glial activation and ALS disease severity. Signiﬁcant correla-
tions between [11C]-PBR28 binding in the primary motor cortex and ALS disease severity
assessed using UMNB and ALSFRS-R were observed. A. Patients with higher UMNB show
increased binding in the motor cortex as shown by a positive correlation between
UMNB scores and SUVR60–90 min in the right precentral gyrus a priori ROI. B. A negative cor-
relation between the ALSFRS-R and SUVR60–90 min in the right precentral gyrus reﬂects the
fact that patients with a higher disability (lower ALSFRS-R score) show increased PBR28
binding in the motor cortex.TSPO radiotracers (Corcia et al., 2012; Turner et al., 2004) as well as
[11C]PBR28 PET studies in other diseases (Fujita et al., 2013; Oh et al.,
2011) have shown that disease-related changes can be observed with
comparable sample size. Based on our current ﬁndings, larger studies
are needed to validate the value of [11C]-PBR28 in ALS and our results
should be considered preliminary pending further testing. Forthcoming
experiments will help understand how the distribution and degree of
[11C]-PBR28 binding change as the disease progresses. Given the pre-
liminary differences observed between individuals with ALS with
bulbar onset vs. limb onset ALS, larger studies enrolling more patients
with bulbar onset will also be required. In addition, studies enrolling a
higher number of participants will help in addressing the topic of
laterality. In our study we observed a larger group difference in the
left hemisphere and correlation with disease severity only in the right
hemisphere. Differences in laterality could be related to handedness of
patients, site of onset, or side with most prominent symptoms at time
of scan. However, given our sample size, interpretations of laterality
are difﬁcult and as previously suggested those questions will need to
be addressed in larger studies or meta-analyses (Bede and Hardiman,
2014). Another potential limitation of the current study is the sole use
of SUV as representation of [11C]-PBR28 binding without performing
kinetic modeling that involves arterial blood sampling. While the
potential to use SUV as a binding metric is a promising characteristic
for image interpretation, future studies with kinetic modeling derived
from arterial blood sampling may need to be conducted to determine
binding potential.
The added value of this study lies in the fact that due to the high
sensitivity of [11C]-PBR28, increased binding can be observed not only
at the group level, but also at the level of individual patients. However,
as it currently stands, [11C]-PBR28 PET is not a diagnostic tool for ALS,
but rather could serve as a pharmacodynamic biomarker to monitor
the efﬁcacy of treatments targeting neuroinﬂammation. This could be
invaluable for evaluation of potential therapeutics in early phase clinical
trials. Finally, the current routine ALS trial entry criteria do not include
any disease biomarkers and are based solely on phenotype, disability
and disease duration. Mechanism-based imaging based on enrollment
of individuals with high levels of [11C]-PBR28 binding could help with
prognostic stratiﬁcation or cohort enrichment in ALS clinical trials, as
it would allow the selection of ALS patients that have more inﬂamma-
tion at baseline and thus may be more likely to respond to certain
treatments. [11C]-PBR28 PET imaging may provide important contribu-
tions to the fundamental question of immune system involvement in
ALS by allowing a mechanistic investigation of the role of activated
microglia. The study of individuals who are pre-symptomatic, but at
high risk of developing the disease, such as superoxide dismutase-1
(SOD1) or C9orf72 gene carriers, may also provide important insights
in this context, as suggested by a previous PET imaging study investigat-
ing pre-symptomatic ALS patients (Turner et al., 2005).
In conclusion, [11C]-PBR28 PET shows increased in vivo glial
activation in individuals with ALS, supporting a role for glial cells in
this disease. Future studies will need to determine its potential as a
pharmacodynamic biomarker to monitor the efﬁcacy of treatments
targeting neuroinﬂammation in ALS.
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